USP general chapter <1503> sets out the quality attributes and tests used to characterize a synthetic peptide drug substance, and a certificate of analysis shows which of them were tested on a sample from one lot, for example identity and purity, and sometimes peptide content, water or counter-ion content. The chapter is a list of what can be measured; a certificate is a record of what was measured, on one sample, by named methods.
The chapter is written for peptide drug substances in pharmaceutical manufacturing. This guide uses its list as a vocabulary for reading certificates issued for laboratory research materials. It describes documents, not materials, and it makes no statement about whether any material meets a USP standard. Where the public record runs out, because the official chapter text is available only by subscription, the guide says so and quotes only what USP publishes openly.
What is USP general chapter <1503>, and what is it not?
The United States Pharmacopeia publishes general chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances, in the USP-NF. A public preview page for the 2021 version sits at doi.usp.org, USPNF_M12935_02_01, the version USP's own peptide standards page links, and newer versions carry the same title: a 2025 version at doi.usp.org, USPNF_M12935_03_01 and a 2026 version at doi.usp.org, USPNF_M12935_04_01. Each preview shows only the chapter's opening paragraph; the full text, including its test table, requires a USP-NF subscription.
USP's records date the chapter precisely. It was new in USP-NF 2021, Issue 2, published February 1, 2021 and official on August 1, 2021, and USP's free Commentary for that issue discusses the chapter's tests.
USP's own guidance fixes the chapter's status. Its answer on identifying official text says that, from a compendial standpoint, general chapters numbered 1000 to 1999 are for informational purposes only and contain no mandatory tests, assays, or other requirements applicable to any official article. Chapter <1503> sits in that range.
USP general chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances, is an informational chapter in the USP-NF, official since August 1, 2021. It describes the attributes and tests used to characterize a synthetic peptide drug substance, but as a chapter numbered between 1000 and 1999 it contains no mandatory tests.
Which quality attributes and tests does <1503> describe?
The chapter's summary table is titled Summary of Tests for Characterization and Quality Control of the Drug Substance. USP's Commentary for USP-NF 2021, Issue 2 discusses that table, and it notes that a footnote marks which tests are advisory rather than mandatory and that the tests are not prescriptive. The Commentary is not official text; USP states that the official text prevails where the two differ. The attributes it names fall into the groups below.
| Attribute group | Tests and notes named in the Commentary |
|---|---|
| Identity | Normally verified by multiple orthogonal techniques, generally including at least one specific test; mass spectrometry, amino acid analysis, peptide mapping and NMR spectroscopy are named |
| Assay and peptide content | Assay normally defined on an anhydrous, counter-ion-free basis; net peptide content by mass balance |
| Peptide-related impurities | Also called related substances; liquid chromatography with mass spectrometry, with a more sensitive high-resolution method preferred for characterization |
| Water content | Coulometric titration (Karl Fischer) named as a commonly used method |
| Counter-ion content | Including residual trifluoroacetic acid |
| Elemental impurities | A test that may be required based on a risk assessment |
| Bacterial endotoxins and bioburden | Named in the comment entries for those tests in the chapter's Table 2 |
| Characterization-only tests | Optical rotation, enantiomeric purity, infrared spectroscopy and higher-level structure, marked for characterization only |
| General characteristics | Color and appearance |
USP's public Commentary on general chapter <1503> names identity, assay and peptide content, peptide-related impurities, water content, counter-ion content including trifluoroacetic acid, elemental impurities, bacterial endotoxins and bioburden, plus characterization-only tests, and it says the chapter's tests are not prescriptive.
Two absences in the public record matter for anyone quoting the chapter. The Commentary does not name residual solvents or acetate as separate <1503> tests, so neither should be attributed to the chapter without reading the official text; both appear in other USP sources covered further on. And because the official table is behind the subscription, the Commentary's description is the most a reader can verify without a USP-NF account.
How does USP's 2023 paper on peptide reference standards list quality attributes?
A 2023 paper in Pharmaceutical Research by USP scientists, with co-authors from the UK medicines regulator (MHRA) and a consultancy, describes how USP characterizes peptide reference standards. It appears in volume 40, pages 1317 to 1328 (PubMed 36949371; open access at PMC10338602). It states that when assessing the quality of a peptide pharmaceutical, the attributes of greatest importance are primary sequence, secondary structure, oligomer or aggregation state, and impurities and degradation products. Its abstract adds that some peptide features, such as chiral or isobaric amino acids, may require additional techniques to ensure a full characterization of the peptide reference standard.
| Attribute | Method named | What the method is used for |
|---|---|---|
| Identity | NMR | Confirm structural features |
| Identity | LC-MS/MS | Peptide mass and amino acid sequence |
| Identity | HPLC | Comparison with a standard or a well-characterized earlier lot |
| Identity | Amino acid analysis | Distinguishing isoleucine from leucine |
| Identity | Chirality | Confirming D-amino acids |
| Purity | Chromatographic purity by HPLC | Quantity of peptide impurities |
| Purity | Acetic acid by HPLC; trifluoroacetic acid by HPLC | Counter-ion content |
| Purity | Residual solvents; residue on ignition | Other residual solvents; inorganic impurities |
| Assay | HPLC | Quantity of the peptide |
The paper also describes how a purity value is assigned to a reference standard: all detectable impurities, such as peptide-related impurities, counter-ion, water, residual solvents and non-combustible residues, are measured and subtracted from 100 percent. Its methods section ties those measurements to USP chapters: water by Karl Fischer titration under <921>, acetic acid under <503>, trifluoroacetic acid under <503.1>, residual solvents under <467> and residue on ignition under <281>.
One caution keeps the two sources apart. The paper does not cite chapter <1503>, so its table is a parallel USP description of peptide quality attributes, not a quotation of the chapter.
Which of these attributes does a research-material certificate report?
A certificate reports the tests that were run, and a research testing laboratory can offer them as a menu. One laboratory that issues certificates for research peptides, Freedom Diagnostics, states on its home page that every COA it issues includes both HPLC purity and LC-MS identity confirmation, and that clients choose any combination of further analyses for each sample, such as net content, endotoxins, heavy metals or pH. A certificate from that laboratory therefore covers the identity and peptide-related impurity groups of the <1503> list and adds others only when they were requested.
| Attribute group | Where it appears on a certificate | If it is not on the certificate |
|---|---|---|
| Identity | An identity line, such as a mass spectrometry result against the expected mass | Identity was not reported for that sample |
| Peptide-related impurities | An HPLC purity percentage, with or without a chromatogram | Purity was not reported for that sample |
| Assay and peptide content | A net peptide content or content line, in mass or percent | Content was not reported; purity does not stand in for it |
| Water and counter-ion content | Separate lines with their own methods, when tested | Not reported; nothing about water or salt can be read from purity |
| Bacterial endotoxins and bioburden | A separate test page or line with its method reference | Not reported; absence is not a negative result |
| Elemental impurities | Separate lines when tested | Not reported |
| Residual solvents (2023 paper's Table II; not named in the public <1503> record) | Separate lines when tested | Not reported |
| Chirality and isoleucine versus leucine (2023 paper's Table II) | A chirality or amino acid analysis line, when tested | Not reported; a mass-based identity line does not settle it, because these variants share a mass |
A research-material certificate reports only the tests requested for that sample, so it covers part of the <1503> list: one research laboratory, for example, includes identity and HPLC purity on every certificate and adds peptide content or endotoxin testing only on request. An attribute missing from a certificate was not reported; it is neither a pass nor a fail.
Why is HPLC purity not the same as peptide content?
The two numbers answer different questions. HPLC purity is the share of the detected chromatographic signal that belongs to the main peptide peak, so it describes the peptide-related impurities the method can see. Peptide content is the share of the material's total mass that is the peptide itself, after water, counter-ions and other non-peptide components are accounted for.
USP's Commentary on <1503> spells out the arithmetic. It says the peptide drug substance assay is normally defined on an anhydrous, counter ion-free basis, and that the easiest approach to determine the net peptide content is a simple mass balance calculation that deducts the percentage of water, of counter ion and, if relevant, of total other non-peptide related impurities from 100 percent.
HPLC purity and peptide content measure different things. Purity is the main peak's share of the detected chromatographic signal; peptide content is the peptide's share of total mass after water, counter-ions and other non-peptide components are subtracted, so a high purity figure can sit beside a lower content figure on the same certificate.
For a reader, the practical rule is to compare like with like. A purity figure from one certificate compares with a purity figure from another only when both name the same method and basis, and a purity figure never answers how much peptide a container holds. The COA interpretation guide shows how to record the basis of each reported value, and the guide to HPLC and mass spectrometry explains the two methods.
What do water and counter-ion tests add to a certificate?
Water and counter-ions are two of the non-peptide components that make up part of a lyophilized peptide's mass. Water is measured by a titration such as Karl Fischer; USP's Commentary names coulometric titration and calls Karl Fischer a commonly used method, and it notes that the water result is required for calculating the assay by HPLC.
Water and counter-ion tests measure two non-peptide parts of a lyophilized peptide's mass: water by a titration such as Karl Fischer, and acetic acid or trifluoroacetic acid under USP chapters <503> and <503.1>. They leave an identity result and an HPLC purity percentage unchanged; they explain the gap between the material's weight and the peptide's weight.
Counter-ions, such as acetate or trifluoroacetate, are part of the material's mass but not part of the peptide. USP's peptide flyer lists the chapters that cover them: <503> for acetic acid in peptides and <503.1> for trifluoroacetic acid (TFA) in peptides, alongside <1052> for amino acid analysis. A certificate that reports a counter-ion line should name which acid was measured and by which method.
That is why USP's Commentary subtracts the percentages of water and counter-ion from 100 percent when net peptide content is calculated by mass balance, and neither line can be read from a purity figure.
What does the companion chapter <1504> cover?
USP general chapter <1504> covers the quality of starting materials used in the chemical synthesis of peptides. Its public preview page says the chapter is intended as guidance on the minimum quality attributes for those starting materials, is limited to the most commonly used protected amino acid derivatives, the Fmoc amino acid derivatives including resin-bound ones, and is to be used in conjunction with <1503>.
USP's records list <1504> as new in USP-NF 2023, Issue 3, official on December 1, 2023, and the Commentary for that issue says the chapter is meant as guidance on minimum quality attributes, not as a set of requirements. Its sections address impurities that originate from amino acids, such as enantiomers and foreign amino acids, and impurities from the manufacturing process of the amino acid derivatives.
USP general chapter <1504> covers starting materials for chemical peptide synthesis, chiefly Fmoc-protected amino acid derivatives, and is meant to be used with <1503>. USP describes it as guidance on minimum quality attributes rather than requirements, and it bears on the synthesis inputs, not on a finished lot's certificate.
What does a certificate that cites USP <1503> actually establish?
A citation of <1503> on a certificate or a product page shows that the author used the chapter's vocabulary. It does not show that every attribute in the chapter was tested, that USP reviewed the material, or that any requirement was met, because the chapter contains no mandatory tests. The useful question is narrower: which attributes were tested, by which method, against which acceptance limit, with which result, on which lot.
Regulated manufacturing sets a useful benchmark for a complete certificate. FDA's questions and answers on control of components, quoting section 11.4 of ICH Q7, describes a manufacturer's certificate of analysis as including, as applicable, the name, grade, batch or lot number, date of release, and a list of each test performed, including the acceptance limits and the numerical results obtained. The passage is written for drug manufacturing; read here, it lists the fields that make a certificate checkable.
A certificate that cites USP <1503> establishes only that its author used the chapter's terms. Because the chapter is informational and contains no mandatory tests, the citation proves nothing about which attributes were measured; the certificate's own test lines, methods, limits and results are the evidence.
How do you read a certificate against the <1503> list, attribute by attribute?
To read a certificate against USP general chapter <1503>, copy each test line with its method, assign each line to one attribute group, and mark every group the certificate does not cover as not reported. The result separates what was measured on that sample from what was left open, without counting an absent test as a pass or fail.
- Copy each test line exactly: the attribute, the method, the acceptance limit if one is printed, and the result with its unit.
- Assign each line to one attribute group: identity, peptide-related impurities, assay or content, water, counter-ion, elemental impurities, bacterial endotoxins or bioburden, or a group the 2023 paper adds, such as residual solvents or chirality.
- Mark each remaining group as not reported, and keep that status separate from any pass or fail.
- Check that the lot, sample name and dates on the certificate match the material the worksheet is about.
- Note any line that names no method or no basis; it cannot be compared with any other result.
The worksheet is deliberately plain. It turns a certificate into a list of measured attributes and a list of open ones, which is the same information a method-scope matrix records in more detail. For the identifiers that tie a certificate to a container, the lot traceability worksheet covers lot, sample, accession and report numbers, and the introductory guide to reading a certificate covers the fields themselves.
Frequently asked questions
Does USP <1503> set mandatory tests for synthetic peptides?
No. USP states that, from a compendial standpoint, general chapters numbered 1000 to 1999 are for informational purposes only and contain no mandatory tests, assays or other requirements, and <1503> is in that range. Its Commentary also notes that the tests in the chapter's summary table are not prescriptive.
Does a certificate of analysis need to report every <1503> attribute?
No. A certificate reports the tests that were run on one sample. A research testing laboratory can offer tests as a menu; one states that every certificate it issues includes identity and HPLC purity, with tests such as net content, endotoxins or pH added only when requested. An attribute that is not printed was not reported.
What is the difference between HPLC purity and peptide content?
HPLC purity is the main peak's share of the detected chromatographic signal. Peptide content is the peptide's share of the total mass after water, counter-ions and other non-peptide components are subtracted, which USP's Commentary describes as a mass balance calculation. One figure does not stand in for the other.
Where can I read USP general chapter <1503>?
USP's DOI preview pages on doi.usp.org show the title and opening paragraph of each version for free. The full chapter, including its test table, is part of the USP-NF subscription. USP's free Commentary for USP-NF 2021, Issue 2 describes the chapter's tests and the changes made to the draft.
Which USP chapters cover acetate and trifluoroacetic acid in peptides?
USP's peptide flyer lists general chapter <503> for acetic acid in peptides and <503.1> for trifluoroacetic acid (TFA) in peptides. Both measure counter-ions, which, like water, are non-peptide components counted in a mass balance.
What does USP general chapter <1504> cover?
Chapter <1504> covers starting materials for the chemical synthesis of peptides, chiefly Fmoc-protected amino acid derivatives, including resin-bound ones. USP describes it as guidance on minimum quality attributes, to be used together with <1503>.
Sources and scope notes
USP statements are quoted or closely paraphrased from public USP pages read on October 4, 2026, Pacific time: the doi.usp.org preview pages for <1503> and <1504>, USP's answer on identifying official text, its peptide standards page and peptide flyer, and its free Commentary for USP-NF 2021, Issue 2 and USP-NF 2023, Issue 3. Official dates come from USP's published ballot records for those issues. The official chapter text, which is available only by subscription, was not read, and USP states that its Commentary is not official text.
The reference standard table is summarized from Table II of the 2023 Pharmaceutical Research paper on peptide reference standards (volume 40, pages 1317 to 1328), read in its open access version; the paper's strength row is summarized as assay. The FDA passage is quoted from question 15 of FDA's questions and answers on control of components, which FDA labels as nonbinding. The laboratory example is quoted from that laboratory's public home page.
This guide describes documents. It does not state or imply that any research material is a drug substance or meets a USP standard, and it does not describe any specific lot or certificate.
- USP, general chapter <1503> preview, USP-NF 2021 version (doi.usp.org) Title and opening paragraph; full text by subscription.
- USP, general chapter <1503> preview, 2025 version (doi.usp.org) Title and opening paragraph.
- USP, general chapter <1503> preview, 2026 version (doi.usp.org) Newest version preview found October 4, 2026.
- USP, general chapter <1504> preview (doi.usp.org) Scope paragraph for starting materials.
- USP, Frequently asked questions: identifying official text Chapters numbered 1000 to 1999 are informational.
- USP, Commentary for USP-NF 2021, Issue 2 Public description of the <1503> tests and revisions; not official text.
- USP, Commentary for USP-NF 2023, Issue 3 Public description of <1504>; not official text.
- USP, cumulative ballot results archive (spreadsheet) Posted and official dates for <1503> in USP-NF 2021, Issue 2 and <1504> in USP-NF 2023, Issue 3.
- USP, Peptide standards (biologics) USP page that links the <1503> preview.
- USP, Peptide standards flyer Lists <503>, <503.1>, <1052>, <1503> and <1504>.
- Pharmaceutical Research 40:1317-1328 (2023), paper on peptide reference standards by USP scientists and co-authors, PubMed record Abstract, Table II quality attributes and methods.
- Same paper, open access full text (PMC10338602) Methods section and Table II.
- FDA, Questions and answers on CGMP: control of components and drug product containers and closures Question 15, certificate of analysis contents per ICH Q7 section 11.4.
- Freedom Diagnostics Testing, home page: tests offered One research testing laboratory's statement of the tests its certificates include.